Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716793 | 0.86 | MAPK1 (0.58) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL6775498 | 0.85 | MAPT (0.65) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL4662535 | 0.83 | MAPT (0.64) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL14212449 | 0.82 | MAPT (0.62) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL11377331 | 0.80 | MAPK1 (0.59) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL21630053 | 0.79 | MAPT (0.59) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL18440448 | 0.79 | MAPK1 (0.59) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL6689472 | 0.79 | OPRK1 (0.64) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL31440674 | 0.79 | MAPT (0.57) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 | |
| SCHEMBL2816931 | 0.79 | ATM (0.46) | MAPK1MAPTPOLBL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| EP-2358202-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010051245-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051245-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | MAPK1 2355/4885MAPT 4800/4885POLB 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.